Bio Rad Laboratories Inc

BIOb

Add to Watchlist

244.800USD

-2.490-1.01%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

Bio Rad Laboratories Inc's Score

Industry at a Glance

Industry Ranking

149 / 206

Overall Ranking

438 / 4490

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

--

Current Rating

--

Target Price

--

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Bio Rad Laboratories Inc Highlights

StrengthsRisks

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Overvalued

The company’s latest PE is 41.01, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.75K shares, decreasing 5.83% quarter-over-quarter.

The current financial score of Bio Rad Laboratories Inc is 7.61, ranking 62 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 592.10M, representing a year-over-year increase of 1.14%, while its net profit experienced a year-over-year increase of 923.59%.

Score

Industry at a Glance

Previous score

7.61

Change

0



Financials

7.95

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.71

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.43

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.71

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.25

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Bio Rad Laboratories Inc is 8.60, ranking 16 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 41.01, which is 5.65% below the recent high of 43.33 and 267.21% above the recent low of -68.58.

Score

Industry at a Glance

Previous score

8.60

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 149/206

Relevant data have not been disclosed by the company yet.

No earnings forecast score is currently available for Bio Rad Laboratories Inc. The Healthcare Equipment & Supplies industry's average is 7.78.

Score

Industry at a Glance

Previous score

0.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Bio Rad Laboratories Inc is 3.64, ranking 194 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 288.98 and the support level at 224.72, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.56

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Blue Raven Partners, L.P.

4.06M

--

Alice N. Schwartz Revocable Trust

437.51K

--

Schwartz (Norman D)

431.47K

+15.22%

Schwartz (Steven D)

38.24K

--

Allison (Schwartz)

4.00K

+1.45%

CSS, LLC

1.04K

-4.95%

Focus Partners Wealth, LLC

760.00

--

Morgan Stanley Smith Barney LLC

692.00

--

Wells Fargo Advisors

170.00

--

Whittier Trust Company

160.00

--



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bio Rad Laboratories Inc is 2.00, ranking 167 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Bio Rad Laboratories Inc

BIOb

4.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bruker Corp

BRKR

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment